<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871622</url>
  </required_header>
  <id_info>
    <org_study_id>16EU01</org_study_id>
    <nct_id>NCT02871622</nct_id>
  </id_info>
  <brief_title>BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM</brief_title>
  <official_title>A Post-market Registry of the BioMatrix Alpha TM (Cobalt Chromium Biolimus A9TM (BA9TM) Drug-eluting Stent)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosensors Europe SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biosensors Europe SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35
      International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical
      practice and will be followed for 2 years for data collection. Major adverse cardiac events
      (MACE) results at 9 months will be compared to the results obtained from the BioMatrix FlexTM
      arm of the LEADERS trial.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Major adverse cardiac events (MACE) in the overall population, defined as composite of cardiac death, myocardial infarction (Q-wave and non-Q-wave), or clinically driven target vessel revascularization (TVR).</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Stable Angina</condition>
  <condition>Ischemia</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>NSTEMI</condition>
  <condition>STEMI</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioMatrix AlphaTM</intervention_name>
    <description>Cobalt Chromium BA9 TM drug-eluting stent</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        &quot;Real world, all comers&quot; patient population: Patients with symptomatic coronary artery
        disease including patients with chronic stable angina, silent ischemia, and acute coronary
        syndromes, who qualify for percutaneous coronary interventions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated with the BioMatrix AlphaTM stent per clinical indication and
             physician's choice;

          -  Patients who agree to comply with the follow up requirements;

          -  Patients with a life expectancy of &gt; 1 year at time of consent;

          -  Patients eligible to receive dual anti platelet therapy (DAPT) according to
             guidelines;

          -  Hemodynamically stable patients.

        Exclusion Criteria:

          -  Inability to provide informed consent;

          -  Currently participating in another trial before reaching primary endpoint;

          -  Planned surgery within 6 months of percutaneous coronary intervention (PCI) unless
             dual antiplatelet therapy is maintained throughout the perisurgical period;

          -  Patient has received an additional stent different from a BioMatrix AlphaTM stent
             during the index procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian BA Menown, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Craigavon Cardiac Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Schuette</last_name>
    <phone>+447 970 942 022</phone>
    <email>d.schuette-consultant@biosensors.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abderrahim Kadri</last_name>
    <phone>+33 176 739 210</phone>
    <email>akadri@cerc-europe.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Craigavon Cardiac Center</name>
      <address>
        <city>Craigavon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chromium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

